BioLine RX Ltd (BLRX) — Strategic Asset Allocation Index
BioLine RX Ltd (BLRX) has a Strategic Asset Allocation Index of 10.6% as of June 2023. Strategic assets (PP&E of ILA2.23 Million plus long-term investments of ILA-) total ILA2.23 Million, measured against net assets of ILA21.05 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BLRX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
BioLine RX Ltd Strategic Asset Allocation Index (2005–2021)
This chart shows how BioLine RX Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2005 to 2021. As of June 2023, the index stands at 10.6%, representing strategic assets of ILA2.23 Million against net assets of ILA21.05 Million ILA. See BLRX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for BioLine RX Ltd (2005–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for BioLine RX Ltd from 2005 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see BioLine RX Ltd stock valuation.
| Year | SAAI | Strategic Assets (ILA) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 3.4% | ILA2.28 Million | ILA2.28 Million | ILA- | ILA68.09 Million | ▼ -8.9 pp |
| 2020 | 12.2% | ILA2.70 Million | ILA2.70 Million | ILA- | ILA22.03 Million | ▲ +1.9 pp |
| 2019 | 10.4% | ILA3.47 Million | ILA3.47 Million | ILA- | ILA33.38 Million | ▲ +5.0 pp |
| 2018 | 5.4% | ILA2.23 Million | ILA2.23 Million | ILA0.00 | ILA41.32 Million | ▼ -1.2 pp |
| 2017 | 6.6% | ILA3.50 Million | ILA2.50 Million | ILA1.00 Million | ILA52.88 Million | ▼ -0.8 pp |
| 2016 | 7.4% | ILA2.60 Million | ILA2.60 Million | ILA- | ILA35.03 Million | ▲ +1.3 pp |
| 2015 | 6.1% | ILA2.91 Million | ILA2.91 Million | ILA- | ILA47.61 Million | ▼ -2.7 pp |
| 2014 | 8.8% | ILA2.80 Million | ILA2.80 Million | ILA- | ILA31.77 Million | ▼ -12.3 pp |
| 2013 | 21.2% | ILA2.47 Million | ILA2.47 Million | ILA- | ILA11.68 Million | ▼ 0.0 pp |
| 2012 | 21.2% | ILA3.17 Million | ILA3.17 Million | ILA- | ILA14.97 Million | ▲ +2.5 pp |
| 2011 | 18.7% | ILA4.21 Million | ILA4.21 Million | ILA- | ILA22.53 Million | ▲ +15.3 pp |
| 2010 | 3.4% | ILA4.51 Million | ILA4.51 Million | ILA- | ILA131.96 Million | ▼ -0.1 pp |
| 2009 | 3.5% | ILA4.17 Million | ILA4.17 Million | ILA- | ILA117.94 Million | ▼ -3.5 pp |
| 2008 | 7.0% | ILA5.48 Million | ILA5.48 Million | ILA- | ILA78.39 Million | ▲ +5.0 pp |
| 2007 | 2.0% | ILA3.73 Million | ILA3.73 Million | ILA- | ILA183.25 Million | ▼ -15.3 pp |
| 2005 | 17.3% | ILA2.21 Million | ILA2.21 Million | ILA- | ILA12.77 Million | — |